Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsSYRE -0.62%26 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates SYRE with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 970 Biotechnology companies, Spyre Therapeutics ranks worse than 103092.68% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Spyre Therapeutics's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Spyre Therapeutics was 0.13. The lowest was -0.02. And the median was 0.05.
SYRE's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Spyre Therapeutics Debt-to-Equity Related Terms
Spyre Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Spyre Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYRE vs CRNX, PTGX, PRAX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Spyre Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (SYRE) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 970 companies in the Biotechnology industry.
Is Spyre Therapeutics' Debt-to-Equity too high?
Spyre Therapeutics' current Debt-to-Equity is 0.00. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 970 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Debt-to-Equity compare to CRNX and PTGX?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 970 companies for Debt-to-Equity. This places Spyre Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (SYRE) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Spyre Therapeutics (SYRE), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score
Get the complete analysis for SYRE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRE has been successfully added to your 
